年轻弥漫大B细胞淋巴瘤患者的中枢神经系统复发:LYSA与GLA/DSHNHL分析
该分析纳入10项德国(GLA/DSHNHL)和法国(LYSA)前瞻性2/3期试验中2203例接受一线R-CHOP、R-CHOEP、R-MegaCHOEP或R-ACVBP后巩固治疗的年轻DLBCL患者。aaIPI 0-1分者中枢神经系统3年累积复发率0%-1%;aaIPI 2-3分者R-ACVBP后为1.6%,R-(Mega)CHO(E)P后为4%(HR 2.4,95%CI 0.8-7.4,P=0.118)。
要点
- aaIPI 0-1分年轻DLBCL患者中枢神经系统3年累积复发率0%-1%,与一线方案及中枢预防无关。
- aaIPI 2-3分年轻高危患者R-ACVBP后3年累积复发率1.6%,R-(Mega)CHO(E)P后为4%。
- R-ACVBP与R-(Mega)CHO(E)P相比HR 2.4(95%CI 0.8-7.4,P=0.118),未达统计学显著。
核心结论
- 对于年轻高危DLBCL患者,包含可透过血脑屏障药物的一线方案可能减少常致命的中枢神经系统复发。
研究设计与样本
- 分析10项德国(GLA/DSHNHL)和法国(LYSA)前瞻性2期和3期试验中2203例接受一线治疗的年轻DLBCL患者。
- 一线方案包括R-CHOP、R-CHOEP、剂量递增R-CHOEP后重复干细胞移植(R-MegaCHOEP)或R-ACVBP后含多种可透过血脑屏障药物巩固治疗。
主要发现
- aaIPI 0-1分患者无论一线治疗及中枢预防如何,中枢神经系统3年累积复发率为0%-1%。
- aaIPI 2-3分年轻高危患者R-ACVBP后巩固治疗的中枢神经系统3年累积复发率为1.6%,R-(Mega)CHO(E)P后为4%。
- R-ACVBP后巩固治疗与R-(Mega)CHO(E)P相比,中枢神经系统复发风险HR 2.4(95%CI 0.8-7.4,P=0.118)。
关键数值与推荐
- aaIPI 0-1分:中枢神经系统3年累积复发率0%-1%。
- aaIPI 2-3分:R-ACVBP后巩固治疗3年累积复发率1.6%,R-(Mega)CHO(E)P后为4%。
- R-ACVBP后巩固治疗 vs R-(Mega)CHO(E)P:HR 2.4(95%CI 0.8-7.4,P=0.118)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most patients with diffuse large B-cell lymphoma (DLBCL) can be cured with immunochemotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients with progression or relapse in the central nervous system (CNS) face dismal outcomes. The impact of more aggressive regimens used in frontline therapy has not been systematically investigated in this context. To this end, we analyzed a large cohort of 2203 younger patients with DLBCL treated on 10 German (German Lymphoma Alliance [GLA]/The German High Grade Non-Hodgkin's Lymphoma Study Group [DSHNHL]) and French (The Lymphoma Study Association [LYSA]) prospective phase 2 and 3 trials after first-line therapy with R-CHOP, R-CHOEP (R-CHOP + etoposide), dose-escalated R-CHOEP followed by repetitive stem cell transplantation (R-MegaCHOEP), or R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycine, and prednisone) followed by consolidation including multiple drugs crossing the blood-brain barrier (BBB). Patients with DLBCL with an age-adjusted International Prognostic Index (aaIPI) of 0 to 1 showed very low cumulative incidence rates of CNS relapse regardless of first-line therapy and CNS prophylaxis (3-year cumulative incidences 0%-1%). Younger high-risk patients with aaIPI of 2 to 3 had 3-year cumulative incidence rates of 1.6% and 4% after R-ACVBP plus consolidation or R-(Mega)CHO(E)P, respectively (hazard ratio 2.4; 95% confidence interval: 0.8-7.4; P = .118). Thus, for younger high-risk patients, frontline regimens incorporating agents crossing the BBB may reduce often fatal CNS relapse.
引用
- Thieblemont C, Altmann B, Frontzek F, et al. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis. Blood Adv. 2023. PMID: 36716220. doi:10.1182/bloodadvances.2022008888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。